About the Company
Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MTCR News
Joshua Makower's Net Worth
Joshua Makower has an estimated net worth of $231 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Cascadian Therapeutics, Inc., Nkarta, Inc ...
Mohamad Makhzoumi's Net Worth
Mohamad Makhzoumi has an estimated net worth of $167 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Arcellx, Inc., Robinhood Markets, Inc ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Regionals 2024
Inc. Regionals honors the fastest-growing privately held companies by region over a two-year period. These are emerging companies. Research shows these firms also tend to be the biggest job ...
Loading the latest forecasts...